SEC 13F Intelligence

Managers / Q4 2018 · view latest →

Tekla Capital Management LLC

CIK 0001300336 · 100 FEDERAL STREET, 19TH FLOOR, BOSTON, MA, 02110 · 617 772-8500

Reported Value
$2.3B
Q4 2018
Positions
203
Filings on Record
19
2019–present window
Filed
Feb 13, 2019
original filing

Summary

Tekla Capital Management LLC reported $2.3B in U.S.-listed holdings across 203 positions for Q4 2018.

Its largest position, JNJ, represents 5.7% of the portfolio.

Portfolio Metrics

Top-10 Concentration
+40.9%
share of reported value
Largest Position
+5.7%
Johnson Johnson

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $2.3BQ4 ’18Q1 ’19: $2.5BQ2 ’19: $2.5BQ3 ’19: $2.3BQ3 ’19Q4 ’19: $2.6BQ1 ’20: $2.2BQ2 ’20: $2.6BQ2 ’20Q3 ’20: $2.7BQ4 ’20: $2.8BQ1 ’21: $2.9BQ1 ’21Q2 ’21: $3.1BQ3 ’21: $3.1BQ4 ’21: $3.1BQ4 ’21Q1 ’22: $2.8BQ2 ’22: $2.5BQ3 ’22: $2.4BQ3 ’22Q4 ’22: $2.6BQ1 ’23: $2.6BQ2 ’23: $2.6BQ2 ’23filingsflow.com

Portfolio Composition

By security type
Common Stock: 81.6%Other: 9.5%ADR: 5.4%REIT: 2.6%US DOMESTIC: 0.4%Other: 0.6%
  • Common Stock · 81.6% · $1.9B
  • Other · 9.5% · $221M
  • ADR · 5.4% · $125M
  • REIT · 2.6% · $61M
  • US DOMESTIC · 0.4% · $10M
  • Other · 0.6% · $13M

Quarter-over-Quarter Changes full breakdown →

IssuerMoveShare ΔShares nowValue ΔValue now
JNJJohnson & JohnsonNEW+1.03M1.03M+$133M$133M
AMGNAmgen Inc.NEW+677.9K677.9K+$132M$132M
BIIBBiogen Inc.NEW+394.9K394.9K+$119M$119M
GILDGilead Sciences, Inc.NEW+1.89M1.89M+$118M$118M
UNHUnitedhealth Group IncorporatedNEW+375.4K375.4K+$94M$94M
CELGCelgene CorporationNEW+1.38M1.38M+$89M$89M
ILMNIllumina, Inc.NEW+262.4K262.4K+$79M$79M
VRTXVertex Pharmaceuticals IncorporatedNEW+426.2K426.2K+$71M$71M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q4 2018

50 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1JNJJohnson & Johnsonhistory →Common5.70%$133M1.03M
2AMGNAmgen Inc.history →Common5.65%$132M677.9K
3BIIBBiogen Inc.history →Common5.09%$119M394.9K
4GILDGilead Sciences, Inc.history →Common5.06%$118M1.89M
5UNHUnitedhealth Group Incorporatedhistory →Common4.00%$94M375.4K
6CELGCelgene Corporationhistory →Common3.79%$89M1.38M
7ILMNIllumina, Inc.history →Common3.37%$79M262.4K
8VRTXVertex Pharmaceuticals Incorporatedhistory →Common3.02%$71M426.2K
9PFEPfizer Inc.history →Common2.83%$66M1.52M
10MRKMerck & Co., Inc.history →Common2.41%$56M738.1K
11REGNRegeneron Pharmaceuticals, Inc.history →Common2.18%$51M136.4K
12ALXNAlexion Pharmaceuticals, Inc.history →Common2.07%$48M496.3K
13ABBVAbbVie Inc.history →Common1.94%$45M492.1K
14Medtronic plcShares1.87%$44M481.4K
15TMOThermo Fisher Scientific Inc.history →Common1.84%$43M191.9K
16INCYIncyte Corporationhistory →Common1.76%$41M645.4K
17Mylan N.V.Shares1.65%$38M1.40M
18ELVAnthem, Inc.history →Common1.59%$37M141.1K
19BMYBristol-Myers Squibb Companyhistory →Common1.45%$34M653.0K
20Allergan plcShares1.34%$31M234.7K
21CVSCVS Health Corporationhistory →Common1.29%$30M460.7K
22ABTAbbott Laboratorieshistory →Common1.21%$28M391.7K
23SYKStryker Corporationhistory →Common1.08%$25M160.4K
24LLYEli Lilly and Companyhistory →Common1.07%$25M216.4K
25NVSNNovartis AGhistory →Sponsored ADR1.07%$25M291.7K
26DHRDanaher Corporationhistory →Common0.92%$22M209.4K
27ZTSZoetis Inc.history →Class A0.92%$22M251.4K
28SRPTSarepta Therapeutics, Inc.history →Common0.90%$21M191.8K
29HUMHumana Inc.history →Common0.84%$20M68.5K
30CNCCentene Corporationhistory →Common0.82%$19M166.9K
31ISRGIntuitive Surgical, Inc.history →Common0.80%$19M39.2K
32TEVATeva Pharmaceutical Industries Limitedhistory →Sponsored ADR0.80%$19M1.21M
33BMRNBioMarin Pharmaceutical Inc.history →Common0.76%$18M207.4K
34AZNNAstraZeneca PLChistory →Sponsored ADR0.70%$16M428.0K
35BSXBoston Scientific Corporationhistory →Common0.67%$16M445.0K
36BDXBecton, Dickinson and Companyhistory →Common0.67%$16M69.8K
37NBIXNeurocrine Biosciences, Inc.history →Common0.66%$15M216.3K
38Jazz Pharmaceuticals plcShares0.61%$14M115.2K
39NVONovo Nordisk A/Shistory →ADR0.60%$14M301.9K
40Omega Healthcare Investors, Inc.Common0.57%$13M380.1K
41SGENUSDSeattle Genetics, Inc.history →Common0.55%$13M226.2K
42CICigna Corporationhistory →Common0.52%$12M64.1K
43ONCBeiGene, Ltd.history →Sponsored ADR0.51%$12M85.8K
44BAXBaxter International Inc.history →Common0.45%$11M161.2K
45SPDR S&P Biotech ETFS&P Biotech ETF0.44%$10M144.4K
46FGENEURFibroGen, Inc.Common0.42%$10M212.8K
47bluebird bio, Inc.Common0.42%$10M98.4K
48Aegerion Pharmaceuticals, Inc.Note 2.00% 8/15/190.42%$10M13.00M
49IDXXIDEXX Laboratories, Inc.Common0.41%$10M51.6K
50SG7Sage Therapeutics, Inc.Common0.40%$9M98.4K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q2 2023$2.6B166Aug 10, 202313F-HRchanges · EDGAR ↗
Q1 2023$2.6B177May 10, 202313F-HRchanges · EDGAR ↗
Q4 2022$2.6B172Feb 10, 202313F-HRchanges · EDGAR ↗
Q3 2022$2.4B169Nov 1, 202213F-HRchanges · EDGAR ↗
Q2 2022$2.5B177Jul 29, 202213F-HRchanges · EDGAR ↗
Q1 2022$2.8B175May 13, 202213F-HRchanges · EDGAR ↗
Q4 2021$3.1B171Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$3.1B172Nov 12, 202113F-HRchanges · EDGAR ↗
Q2 2021$3.1B189Aug 13, 202113F-HRchanges · EDGAR ↗
Q1 2021$2.9B196May 14, 202113F-HRchanges · EDGAR ↗
Q4 2020$2.8B200Feb 12, 202113F-HRchanges · EDGAR ↗
Q3 2020$2.7B204Nov 13, 202013F-HRchanges · EDGAR ↗
Q2 2020$2.6B222Aug 13, 202013F-HRchanges · EDGAR ↗
Q1 2020$2.2B217May 14, 202013F-HRchanges · EDGAR ↗
Q4 2019$2.6B214Feb 13, 202013F-HRchanges · EDGAR ↗
Q3 2019$2.3B192Nov 13, 201913F-HRchanges · EDGAR ↗
Q2 2019$2.5B197Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$2.5B194May 14, 201913F-HRchanges · EDGAR ↗
Q4 2018$2.3B203Feb 13, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.